Bortezomib-thalidomide-dexamethasone incorporated into autotransplantation is associated with more favorable outcomes after relapse in comparison with thalidomide-dexamethasone plus autotransplantation in multiple myeloma

This article has no abstract
Epistemonikos ID: 14770fa311dcbcd9603f912d4f9aedefb2235169
First added on: Feb 05, 2025